Cline Scientific provides an update on the company’s financial position

Cline Scientific AB (publ) ("Cline" or the "Company") would like to provide the following update on the company's financial position with reference to the previous press release on January 18th.

The board has continued to work to find solutions to strengthen the company's financial position in both the short and long term. This work has not yet yielded any results and no decision regarding the company's appeal against the rejection to its application in the EIC accelerator has been received. The board continues this work with undiminished vigour.

Currently, the company's working capital is estimated to last through August 2024.

The company is listed on the Nasdaq First North Growth Market. Redeye AB is Cline Scientific's Certified Adviser.

 This information is information that Cline Scientific is required to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication by the contact person set out above, at  10:05 am CEST on 30 April 2024.

For more information, please contact:
Patrik Sundh, CEO
Email: patrik.sundh@clinescientific.com
Phone: +46 0703585088

Cline Scientific AB (publ)                                                
Pepparedsleden 1
AstraZeneca BioVentureHub                                               Email: info@clinescientific.com
431 53  MÖLNDAL                                                             Website: www.clinescientific.com

About Cline Scientific
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. Cline’s unique patented surface nanotechnology provides solutions to critical challenges for cell-based products and process in Life Science. Cline is driving two projects through to a clinical stage, StemCART - a stem cell therapy for joint repair, and CellRACE- a cancer diagnostic to predict metastasis.